CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular LymphomasNext-generation prognostic assessment for diffuse large B-cell lymphomaConstitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell LymphomaTumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityBET inhibitors in the treatment of hematologic malignancies: current insights and future prospectsRadiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment optionProposing Essential Medicines to Treat Cancer: Methodologies, Processes, and OutcomesApproach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryDiffuse large B-cell lymphoma: current strategies and future directionsPreserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma.Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant diseaseA new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absentRate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationClinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.Vincristine-induced vocal cord palsy and successful re-treatment in a patient with diffuse large B cell lymphoma: a case report.Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy.Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma.CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma--a meta-analysis of randomized controlled trials.Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy.Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.Consolidation Radiotherapy in Stage IE- IIE, Non-Bulky Primary Gastric Diffuse Large B-Cell Lymphoma with Post-Chemotherapy Complete Remission.Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.Successful treatment of cryoglobulinaemia with rituximabMutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyA phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis.Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma.Prognostic value of interim (18)F-FDG PET/CT in diffuse large B-cell lymphoma
P2860
Q24597424-FB13FED9-5A73-42BC-9DA6-8D4124D97671Q26752284-33BBBC81-FDDD-4990-9279-2496B90E7A82Q26796428-58FEF5FF-ED16-4E40-B341-04947F46125CQ26853170-0BA3446A-B5E8-43F5-BB85-8E48D59DF571Q26862220-6824C331-323A-482B-BEF8-EFE4D7FC98D6Q28066765-4A76F920-C908-4EDE-B0E8-668DB50471BDQ28079951-B7290575-9008-44FC-B8CC-B1D89506C4E9Q28081319-13C63111-2738-404D-93F1-AC664225148AQ28088365-F6EC4BC6-67FC-4A93-8312-D1066D4B4C0FQ28269136-542F1D48-B6EE-4FD2-A24D-ACF8B085AA97Q30764873-A774D9A6-53C7-4E6E-8A08-06A9D89134ACQ33406742-D0344E56-C3AA-4485-8C77-2C0B2F592139Q33416550-32E6C0B0-DDE2-4F2E-A799-F6275704D7C1Q33417548-2B65A502-7CEA-47A3-BC63-F2420169CA4CQ33564294-0CBA2D02-6936-40BA-8B0F-540BB827B7B0Q33875883-FFB54CB9-BF29-4B15-9304-D94B622EE732Q33911781-0F7D4451-4D6A-4D88-B6D9-1C82E7B8A350Q33945770-41B97080-5D02-4860-9508-84DA905FD198Q34257135-7FCE865B-17F4-41D8-8A6E-435D86A9730AQ34325329-DE2D97E0-AAA2-4EF5-B2E3-C53432FAFAE1Q34365673-47731FB8-5A06-4C4F-A56E-E5A27B97BDFCQ34460823-A9819DE8-E2D9-4474-870A-3DC2A71D7756Q35179212-F70E3879-9343-4794-A647-E044657B97D0Q35218039-149B6862-BB3D-441E-8E5A-7C5FB343AAB2Q35236068-3EE2F9D3-B72D-47D8-9A1E-DA2B54E7E857Q35260446-ADFC8E1F-E1DC-40EF-82CB-311BCAE24252Q35638549-7AB9AC51-0B6A-4BFE-8333-13046AE43B87Q35656926-56B0C5FC-1386-453D-9155-289035EA5178Q35674557-71A2D9B3-6ABA-4F51-BC7F-C6A475108AD6Q35700505-A46EFF46-F55B-46DB-8FA7-334CBCE54B3AQ35800846-E49BF5CE-07F7-48B6-8906-0142B5A07CB2Q35834336-48B256E5-C7F7-402F-BBFF-F792D986AB07Q35995248-32305DF6-4F4F-4E07-A38F-F30C8F4CB9E2Q36068667-3C81896F-0470-44C5-B1EB-FD08543A09CAQ36350120-85C4E7E7-B48F-4E15-9011-1DD30863521AQ36395599-F4A50F07-373D-4050-9DE0-2BBB9C83A05BQ36404383-2BF8258F-164D-4AB1-953C-4F51AC9DBB17Q36411549-3E124292-2D8C-4148-9C61-741F70455B80Q36524619-9E98CB0F-3A71-440E-9FEF-4097BEB692B9Q36563201-15F2A48B-E753-44E8-B498-B8E5A840D219
P2860
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
CHOP-like chemotherapy with or ...... ernational Trial (MInT) Group.
@en
CHOP-like chemotherapy with or ...... e MabThera International Trial
@nl
type
label
CHOP-like chemotherapy with or ...... ernational Trial (MInT) Group.
@en
CHOP-like chemotherapy with or ...... e MabThera International Trial
@nl
prefLabel
CHOP-like chemotherapy with or ...... ernational Trial (MInT) Group.
@en
CHOP-like chemotherapy with or ...... e MabThera International Trial
@nl
P2093
P1433
P1476
CHOP-like chemotherapy with or ...... ernational Trial (MInT) Group.
@en
P2093
Anders Osterborg
Armando López-Guillermo
Devinder S Gill
Evelyn Kuhnt
Jan Walewski
Lois Shepherd
Lorenz Trümper
MabThera International Trial (MInT) Group
Markus Loeffler
Niels Murawski
P304
P356
10.1016/S1470-2045(11)70235-2
P577
2011-09-21T00:00:00Z